Reviewed by … Please wait …- China Industry Report – Focus blog
Chapter 2007, the main areas of international market conditions <> a, all cones pharmaceutical market conditions <> (a) all cones in 2007 pharmaceutical market development <> (b) all cones Medicine 2007 market sales by region <> (C) 2007 All cones main types of treatment and its sales rankings <> (d) all cones in 2007 and its best-selling prescription drug sales growth analysis <> (E ) development of new drugs in 2007 and beyond trend <> Second, the world’s conversion of non-prescription drug market analysis <> (a) Rx to OTC conversion of the overall trend <> (b) Rx to OTC conversion of the driving force <> (c) Rx to OTC conversion of the security <> Third, the U.S. pharmaceutical industry Analysis <> (a) the overall 2007 sales analysis <> (b) the total area of 2007 Top Ten Treatment is the target investment by pharmaceutical manufacturers <> (c) best-selling drugs in 2007 sales analysis <> (D) 2007 ranking of America’s top ten pharmaceutical companies <> (e) sales channels of <> 4, the Japanese pharmaceutical industry Analysis <> (a) the overall Japanese pharmaceutical market overview <> (2) Japan Kampo medicine production profile <> (c) the internationalization of the Japanese pharmaceutical market change in the situation <> V. Analysis of the European pharmaceutical industry <> (a) the European pharmaceutical market overview <> (ii) European pharmaceutical market analysis <> <> Chapter 2007 of the international pharmaceutical business leader analysis <> a, all cones overall leader in pharmaceutical analysis <> (a) the overall business situation analysis <> (B) Analysis of R & D <> (c) the overall 2007 sales < ;> (d) new product development and market situation analysis <> Second, Roche <> Third, the Pepsi-Myers Squibb <> Fourth, Novartis Pharmaceuticals <> V. Merck <> six, GlaxoSmithKline <> seven, South India, Star Pharmaceuticals <> 8, the world’s leading biopharmaceutical company in recent years, the operation of <> (a) Serono company situation analysis <> (b) An operation in 2003 into the analysis of <> <> Chapter III of the 2007 International Pharmaceutical R & D Analysis <> a, pharmaceutical research and development of all cones <> (a) Analysis of the world’s pharmaceutical research and development <> (b) the world’s pharmaceutical research and development of the main problems encountered <> Second, all cones patent drug options <> (a) the patent has expired or will expire drug <> (b) 1998-2007 all cones selling drug patent expiration <> (c) All research and development of antiviral drugs cones <> <> Chapter 2007, China’s pharmaceutical policy environment <> First, the drug management policy analysis <> (a) the new drug approval policy analysis <> (b) pharmaceuticals policy analysis <> (c) the food and drug safety policy analysis <> (IV) drugs recall system analysis <> (e) drug regulatory policy analysis <> Second, the drug price policy analysis <> (A) Drug price adjustment policy analysis <> (b) the policy of drug retail market is facing analysis <> (c) the policy impact analysis of drug R & D <> (d) the impact of tax policy analysis <> Third, China’s medical reform of the pharmaceutical industry impact analysis <> (a) China Pharmaceutical business impact analysis <> (b) the competitive landscape of China’s pharmaceutical enterprises influence <> (c) the impact of China’s medical device company analysis <> (d) investment in China’s pharmaceutical industry impact analysis <> ; (e) the impact of China’s pharmaceutical market analysis <> <> Chapter 2007 analysis of China’s pharmaceutical industry R & D <> a, all cones Pok basic health research <> (a) Full cones pharmaceutical research and development trend analysis <> (b) hot spot analysis of 2007 <> 1, blockbuster drugs <> 2, the main direction of research and development – disease treatment <> 3, all cones most drug development Ten active in the field <> Second, China’s R & D status <> (a) the Chinese synthetic drug development status and prospects <> (II) China’s pharmaceutical enterprises break through drug development <> <> first VI 2007 Analysis of China’s pharmaceutical industry is running <> First, the Chinese pharmaceutical industry operation analysis <> (A) 2007 top ten pharmaceutical manufacturing business statistics <> (b) pharmaceutical export base in 2007 City export statistics <> (c) 2007 pharmaceutical manufacturing statistics of major economic indicators <> (D) 2007 Pharmaceutical Manufacturing sub-regional indicators statistics <> (e) 2007, China’s pharmaceutical market demand for international statistics <> (f) 2007 Drug Import and Export Statistics of China <> (vii) economic performance in 2007 the pharmaceutical industry analysis <> Second, the Chinese pharmaceutical industry, market demand analysis <> (a) of Chinese Pharmaceutical Industry concentration status <> (II) concentration of China’s pharmaceutical industry empirical study <> (c) China’s pharmaceutical industry is facing a strategic transition <> (d) the potential of China’s rural market analysis of medicine consumption <> (E) China market adjustment facing the pharmaceutical industry <> Third, China’s pharmaceutical industry development opportunities analysis <> (a) China’s pharmaceutical industry is facing three major new opportunities <> (b) the development of China’s pharmaceutical industry opportunity analysis <> (c) four favorable factors support the development of the pharmaceutical industry <> Fourth, the development of China’s national pharmaceutical industry analysis <> (a) organize and explore China’s national medical research subjects Pok <> ; (b) the Chinese folk medicine and medical institution-building <> (c) the development prospects of China’s national pharmaceutical industry analysis <> <> Chapter VII of the Chinese pharmaceutical industry review in 2007 and 2008 Prospects <> First, the development of the pharmaceutical industry in 2007 Review <> (a) Industrial growth momentum continued <> (b) Commercial and stable development of <> (c) the level of efficiency and little decrease <> (d) the retail terminal The battle intensified <> (e) the rural consumer market healthy start <> (f) pharmaceutical market continued to show a multi-level consumption pattern <> (g) space is still falling corporate profits <> ( h) to increase market supervision <> (i) reduced costs of modern logistics efficiency into key business <> (X) to enhance the international competitiveness of enterprises is still the proposition <> (1) of the bottleneck to be address <> In 2008 the pharmaceutical industry Prospects <> (a) attempt to grasp the future trends in the development <> (b) will further accelerate the industry reshuffle <> (c) the structure and quality of urban and rural consumption continue to enhance the <> (d) market linkage to the future flow of new Bureau <> (e) under the new situation, new research to develop marketing strategies <> Third, the pharmaceutical industry in the future development trend analysis <> <> ; Chapter VIII of the 2007 Review assessment of China’s pharmaceutical industry hot <> a, GMP certification analysis <> (a) GMP certification impact on the market <> (b) is concerned about small and medium sized pharmaceutical companies GMP certification <> (c) GMP certified pharmaceutical industry after China’s overall surplus production capacity is still increasing <> (d) GMP certification after the era of marketing to <> (e) How will the pharmaceutical companies to consolidate and expand the GMP certification results < ;> Second, analysis of mergers and acquisitions boom <> (a) Perspective pharmaceutical mergers and acquisitions FY <> (b) restructuring of the pharmaceutical industry’s motives, characteristics and trends <> (c) the causes of China’s pharmaceutical industry mergers and acquisitions and Characteristics <> (iv) International pharmaceutical companies and the acquisition of Dynamic Analysis of the Implications of China <> (E) 2004 Buzz pharmaceutical industry mergers and acquisitions, restructuring climax <> (F) M & A will be the Chinese medicine rapid industrial development of the theme <> (g) of the pharmaceutical industry M & A forecast analysis <> <> Chapter IX of the development of China’s pharmaceutical industry Analysis <> First, pharmaceutical companies strategy perspective < ;> (a) positioning <> (b) product <> (c) the customer <> (D) personnel <> Second, the pharmaceutical industry development analysis <> (A) Overall differentiation was depressed bipolar <> (II) complex issues to shoulder <> (C) and Forth Jie retreat, according to <> Third, the profits of the pharmaceutical industry to explore new point <> Fourth, the medical how to choose the technology innovation business model <> (a) medical technology innovation model <> (b) trends in the management of technological innovation <> (c) China’s pharmaceutical business innovation model selection <> five China’s pharmaceutical manufacturing technology innovation fatigue cause analysis <> (a) industrial organization factors <> (b) basic research aspects <> (c) intellectual property protection factors <> six vertical pharmaceutical companies on crisis and turnaround <> (a) changes in the environment and more <> (b) God helps those who help themselves <> seven research and development of China’s pharmaceutical industry analysis <> (a) the pharmaceutical industry chain < ;> (b) foreign pharmaceutical R & D investment and operation of the contrast <> (c) the development of Chinese pharmaceutical companies becoming zero force Whose Fault <> (d) the consequences of zero R & D trend <> <> Chapter 2007, the pharmaceutical industry Consumer Analysis <> First, the basic situation of consumers <> (a) the composition of urban and rural population in all regions <> (b) of the National People’s living standard <> ; Second, structural analysis of drug consumption <> (a) urban and rural consumption structure <> (II) China’s rural pharmaceutical market <> (c) the domestic drugs and imported drugs, the market share of joint venture pharmaceutical <> ; Third, analysis of consumer psychology <> (a) psychological analysis of consumer purchase of medicines <> (b) the choice of consumers in the Western <> (c) the patient medical habits <> (d) patient understanding of the main channel of new drugs <> (e) use of hospital purchasing habits and attitudes <> Fourth, consumers standing drug analysis <> (a) the family standing three drugs <> (b) the purchase of medicines standing channel <> Fifth, changes in disease incidence patterns <> (a) the incidence of the 21st century, the changing patterns of all cones <> (II) China’s population disease incidence patterns <> ; <> Chapter bulk drugs industry in China run Pok Analysis <> a, of the overall operation of Pok API <> (a) of the 2007 Pok bulk drug industry profit and loss situation <> (b) of the 2007 Pok bulk drug industry sales of <> (c) API 2007 of the efficiency of the sector of Pok <> (d) of the 2007 Pok API industry development index <> two , of Pok operation analysis of economies of scale API <> (a) API 2007 of Pok medium and small enterprises profit and loss situation <> (b) API 2007 of curb production and marketing of medium and small enterprises <> ( c) API 2007 of Pok-effectiveness of medium and small enterprises <> (d) of the 2007 Pok API medium and small enterprises development index <> Third, the economic ownership of Pok API operation analysis <> (a) API 2007 of curb economic losses of property <> (b) API 2007 of Pok economic production and marketing of property <> (c) 2007 property of Pok API economic situation <> (d) API 2007 of title Pok economic development index <> Fourth, the production of bulk drugs of Pok Analysis <> (A) 2007 annual growth <> (II) of 2007 Pok material changes in monthly drug <> (c) the main areas of Pok production of bulk drugs <> Fifth, Pok API leader of the operation <> Sixth, China’s foreign trade situation of Pok analysis of bulk drugs <> <> Chapter XII preparations industry in China run Pok Analysis <> First, agents of the overall operation of Pok <> (a) preparation of the industry in 2007 profit and loss situation of Pok <> ; (b) 2007 industry sales of formulations of Pok <> (c) 2007 industry-effectiveness of Pok preparation <> (d) of the 2007 Pok preparation industry index <> Second, of Pok agents economies of scale <> (A) 2007 preparation of medium and small enterprises profit and loss situation Pok <> (II) of 2007, sales of medium and small enterprises Pok preparation <> (c) 2007, agents of Pok medium and small enterprises benefit of <> (D) 2007 Pok preparation of medium and small enterprises development index <> Third, the economic ownership of Pok preparation <> (a) the property in 2007 of economic profit and loss situation Pok preparation <> (b) property agents in 2007 of economic production and marketing of Pok <> (c) the property in 2007 economic conditions of Pok preparation <> (D) 2007 Pok preparation of economic development property index < ;> four main areas of operation Pok preparation <> (a) overall <> (b) preparation industry in Jiangsu Province of Pok operation <> (c) preparation of the Guangdong region of Pok run industry of <> (D) in Shanghai Industrial preparation of the operation of Pok <> (e) preparation industry in Zhejiang province of Pok operation <> (f) preparation industry in Shaanxi province of Pok operation <> (g) preparation of the Beijing area of Pok industrial operation <> (h) preparation industry in Shandong Province of Pok operation <> (i) preparation industry in Henan operation of Pok <> (x) four area of operation of Pok preparation industry <> Fifth, leader of the operation of Pok preparation <> June, China’s foreign trade situation analysis of Pok preparation <> (a) the export of agents in 2007 the general situation of Pok <> (b) imports and exports in 2007 <> (c) the preparation of the export of Pok <> <> Chapter XIII China Chinese Herbal Medicine industry development trend analysis <> First, run the whole Chinese Herbal Medicine of <> (a) Chinese Herbal Medicine Industry in 2007 profit and loss of <> (b) 2007 industry sales of Chinese Herbal Medicine <> (c) 2007 efficiency of the sector of Chinese Herbal Medicine <> (D ) 2007, Chinese Herbal Medicine Industry Development Index <> Second, economies of scale Chinese Herbal Medicine <> (a) medium and small enterprises in 2007 profit and loss situation of Chinese Herbal Medicine <> (II) 2007 Chinese Herbal Medicine and sales of medium and small enterprises <> (c) 2007 medium and small enterprises benefit of Chinese Herbal Medicine <> (d) of medium and small enterprises in 2007 Chinese Herbal Medicine Development Index <> Third, the economic rights Chinese Herbal Medicine <> (a) Chinese Herbal Medicine in 2007 profit and loss situation of economic property rights <> (b) the economic rights in 2007 and sales of Chinese Herbal Medicine <> (c) 2007, Chinese Herbal Medicine economic benefits of ownership <> (d) of Chinese Herbal Medicine 2007 Index of economic development property <> Fourth, the operation of the main areas of Chinese Herbal Pieces <> (a) overall <> (b) in Guangdong Province <> (c) in Guangxi region <> (D) four region <> (e) in Jiangsu Province <> (VI) in Jilin <> (g) in Zhejiang Province <> Fifth, Chinese Herbal Medicine leader in the operation <> <> Chapter XIV Chinese medicine industry operating status analysis <> First, the overall operation of medicine <> (a) profit and loss situation of Chinese patent medicine industry in 2007 <> (b) sales of Chinese patent medicine industry in 2007 <> (c) the efficiency of the sector of medicine in 2007 <> (D) 2007 Chinese patent medicine industry development index <> Second, economies of scale medicine <> (a) medicine in 2007 medium and small business profit and loss situation <> (II) 2007 Chinese medicine production and marketing of medium and small enterprises <> (c) 2007 medium and small enterprises benefit of medicine <> (d) a large proprietary 2007 SME Development Index <> Third, the proprietary property of economic <> (a) economic losses in 2007 proprietary rights situation <> (II) in 2007 and sales of proprietary economic property rights <> (C ) proprietary rights in 2007 economic conditions <> (d) economic development in 2007 proprietary rights index <> Fourth, medicine production situation analysis <> (A) 2007 annual growth <> (b) changes in January 2007 production degree <> (c) 2007 production of the main areas of medicine <> five major regions proprietary operation <> (a) overall <> (b) in Guangdong Province <> (c) in Jilin <> (D) in Guizhou Province <> (E) Shandong <> (f) four region <> (g ) in Zhejiang Province <> (h) Tianjin <> (IX) in Beijing <> <> Chapter XV of the world’s biopharmaceutical industry operation analysis <> a, all cones biological system Pharmaceutical market size <> Second, all cones of listed companies, biotechnology companies <> Third, all cones biopharmaceutical industry trends <> (a) all cones forecast <> (b) the international market present and future best-selling biological drugs <> (c) the recent (2007 years) will be put into production and selling drugs under development <> Fourth, the U.S. biopharmaceutical industry conditions <> (a) American Institute of Biological technology industry in 2007 to reproduce the rise <> (b) highly sought after capital became the upstart biotech company <> Fifth, bio-pharmaceutical industry in Japan <> (1) Japan biopharmaceutical industry conditions <> (b) the size of Japan’s biotechnology industry forward <> (c) the protein structure of Japan’s achievements <> six bio-pharmaceutical industry of Germany <> seven, the world’s leading bio-pharmaceutical products market status <> (a) the general situation analysis <> (b) of the world’s genetically engineered drugs industry analysis <> (c) 2008-2010 all cones therapeutic protein market analysis and forecasting <> < ;> Chapter XVI China’s biopharmaceutical industry analysis <> First, the overall operation of biopharmaceutical <> (A) 2007 bio-pharmaceutical industry profits and losses of <> (II) 2007 bio- production and marketing of pharmaceutical industry <> (c) 2007 bio-pharmaceutical industry effectiveness of <> (D) 2007 bio-pharmaceutical industry development index <> Second, economies of scale biopharmaceutical <> ; (a) medium and small enterprises in 2007 profit and loss of bio-pharmaceutical <> (II) 2007 bio-pharmaceutical production and marketing of medium and small enterprises <> (c) 2007 bio-pharmaceutical benefits of medium and small enterprises < ;> (D) 2007 medium and small enterprise development, biopharmaceutical Index <> Third, the economic biopharmaceutical property <> (a) the property in 2007 the economic loss situation biopharmaceutical <> (II) In 2007 ownership of economic production and marketing of biopharmaceutical <> (c) 2007 economic conditions biopharmaceutical property <> (D) 2007 Index of economic development biopharmaceutical property <> Fourth, the biological system Pharmaceutical industry regional development <> (a) comparison of regional economies in 2007 <> (II) bio-pharmaceutical industry in 2007, Hubei operation analysis <> (C) 2007 Zhejiang biopharmaceutical industry operation analysis <> (D) 2007 bio-pharmaceutical industry in Shandong operation analysis <> (E) 2007 Shanghai biopharmaceutical industry operation analysis <> (f) 2007 Guangdong biopharmaceutical industry operation analysis <> (g) 2007 Beijing biopharmaceutical industry operation analysis <> (h) 2007, Tianjin biopharmaceutical industry operation analysis <> (i) biological systems, Jiangsu, 2007 Pharmaceutical industry operation analysis <> <> Chapter XVII Chinese biopharmaceutical market segment analysis <> a, blood products industry market analysis <> (a) the definition and classification of blood products <> (b) blood products industry is characterized by <> (c) analysis of the international blood products industry <> (D) plasma collection methods on the impact of China blood products industry <> (E) China blood products industry market conditions <> (F) China blood products industry, the competitive landscape <> (g) the development of China blood products industry trend <> Second, the vaccine industry overview <> (a) vaccine definition and classification of <> (b) the history of vaccine development <> (c) 2007-2009 the international vaccine market forecast <> (D) 2003-2007 Chinese vaccine industry R & D and supply conditions <> Third, the overall supply of diagnostic reagents market conditions like <> Fourth, domestic market sales of interferon status <> (a) the main types of interferon production <> (b) market space <> (c) increasing competition <> (D) growth will take time <> (e) of the current production of interferon listed companies <> Fifth, other segments of <> ; (a) human serum albumin <> (b) erythropoietin <> (C) IL <> (d) colony-stimulating factor <> (e) human growth hormone < ;> (f) insulin <> <> Chapter XVIII of 2007, China’s import and export of bio-pharmaceutical analysis <> a, the major bio-pharmaceutical products imports in 2007 <> (a ) major biopharmaceutical products and the amount of total imports of <> (b) bio-pharmaceutical products importing countries of the <> Second, the major bio-pharmaceutical products exports in 2007 <> (a) biological pharmaceutical products mainly export volume and value of <> (b) bio-pharmaceutical products are mainly exported to countries of the <> <> Chapter XIX Chinese hospital drug market segment analysis of the major pharmaceutical <> a , macrolide antibiotics, hospital drug analysis <> (A) macrolide drugs market growing steadily <> (b) macrolides anti-infective market competition situation analysis <> 1, macrolides manufacturers of anti-infective market analysis <> 2, macrolides anti-infective market concentration analysis <> (c) macrolides main varieties of anti-infective market growth analysis <> (D) macrolides varieties of anti-infective market analysis <> (e) the development prospects of macrolide antibiotics <> Second, the anti-hypertensive drugs Hospital treatment analysis <> (a) market conditions in the international anti-hypertensive drugs <> 1, the foreign anti-hypertensive drug market overview <> 2, the foreign anti-hypertension drug market characteristics and forecasts <> ( B) of anti-hypertensive drugs in general market conditions <> 1, anti-hypertensive drugs the hospital market analysis <> 2, anti-hypertensive drugs the hospital market share analysis <> 3, anti-hypertensive drugs of all varieties hospital market share analysis <> 4, anti-hypertensive drug manufacturers hospital market share analysis <> 5, anti-hypertension drugs market growth rate analysis of all varieties <> Third, the analysis of lipid-lowering drug treatment hospital < ;> (a) cholesterol-lowering drug market analysis <> (B) cholesterol-lowering drug market competition in the <> 1, the cholesterol-lowering drugs market share trend <> 2, the cholesterol-lowering drug manufacturers market share trend <> 3, lipid-lowering drugs, primarily varieties of market growth analysis <> Fourth, anti-thrombosis drug hospital market analysis <> (a) analysis of market demand and size of <> (b) all cones antithrombotics market conditions <> (c) the overall domestic market conditions antithrombotic drugs <> 1, anti-thrombosis drug market capacity analysis <> 2, anti-thrombosis drug market analysis <> 3, variety of hospital antithrombotic drugs market analysis <> 4, anti-thrombosis drug manufacturers to the hospital market share analysis <> 5, anti-thrombosis drug market growth rate analysis of all varieties <> 5, China’s major cities plant alkaloids antineoplastic market analysis <> (A) of the current status of cancer incidence analysis <> (B) of the plant (natural type) analysis of antineoplastic agents in clinical status <> (c) near Ji, China plant (natural class) anti-tumor analysis of market competition, all varieties <> six ophthalmic drug market analysis <> (A) Eye Overview <> (b) status of ophthalmic drug development <> 1, the development of new routes and new dosage forms <> 2, the development of new drugs <> (c) of ophthalmic drugs in general market conditions <> 1, the ophthalmic drug market capacity analysis <> ; 2, ophthalmic drug market share analysis <> 3, ophthalmic drug manufacturers market share analysis <> 4, the main varieties of ophthalmic drugs market growth analysis <> seven penicillin-type drugs sales analysis of national hospital < ;> 8, amoxicillin / clavulanate potassium hospital drug analysis <> (a) medical treatment – the growth rate is slowing down <> (b) the domestic manufacturers – market share reallocation <> (c) the market share – rising foreign drug Sinopharm down <> September, the hospital drug vancomycin Analysis <> (a) the total amount of medication status of vancomycin <> (b) vancomycin sub-prime city drug use <> (c) status of vancomycin manufacturers sales <> (d) the proportion of domestic and imported <> October, Β-lactamase inhibitor hospital market analysis <> XI cephalosporins drug use analysis <> XII Couinaud priority species ketones drug analysis <> (A) levofloxacin <> (b) ciprofloxacin <> (C) ofloxacin <> (d) of fleroxacin <> (E) norfloxacin <> (f) gatifloxacin <> XIII, systemic steroids hospital drug use analysis <> fourth, secret Analysis of hospital drug treatment <> fifth, digestive system drugs the hospital market analysis <> XVI respiratory drug market <> (a) of the hospital in 2007 respiratory drugs market trend <> (b) The Hospital Respiratory medicine category market analysis <> (C) The main varieties of market conditions <> (D) respiratory drug retail market analysis <> (E ) asthma drug market analysis <> XVII 2007 for external use Chinese dermatology market analysis <> (a) overall in 2007 <> (b) market characteristics <> (c) the specific brand analysis <> eighth, lipid-lowering drugs <> ninth, the situation of China’s diabetes drug market analysis <> <> Chapter retail sales of China pharmaceutical analysis <> First, the overall analysis <> (a) the overall retail market in the year 2007 the situation <> (b) of the 2007 Pok amount of drugs and medicine sales order <> (c) the amount of business sort of sales <> (d) of the retail pharmaceutical market in 2007 the amount of the top 50 of <> Second, the pharmaceutical retail market share in January Analysis <> (a) pharmaceutical companies pharmaceutical retail market share performance of the month <> (b) by Zhao in 2007 the amount of medicine and number of retail brands sort of <> Third, the main regional pharmaceutical retail market <> (a) in Beijing <> (b) the Shanghai area <> (c) in Wuhan <> (D) in Guangzhou <> (E) Shenzhen <> (VI) in Hangzhou, <> <> Chapter XXI Chinese pharmaceutical industry Marketing Strategy Analysis <> First, adjust the marketing strategy analysis of pharmaceutical companies <> Second, the <> (a) the implementation of China’s pre-tender drugs the pharmaceutical industry marketing model <> (b) implementing drug bidding on the impact of China’s pharmaceutical industry <> (c) after the implementation of the drug tender Rethinking <> Fourth, the interpretation of pharmaceutical companies marketing points <> (a) the relationship between the customer base tree structure adjustment <> (b) manage the flow of fine <> (c) the strict management of the internal sales force <> ; V. On the value of pharmaceutical business development channel <> (a) pure specialization only imagine <> (b) vendor integration is a dynamic equilibrium <> (c) more than the sights on the consumer <> six, pharmaceutical e-commerce into the trend of <> (a) medical e-commerce has become the trend <> (b) channel analysis <> (a) to widen the channel method <> (b) strength against the law <> (c) the interference caused the collapse of law <> (d) comprehensive policy package method <> ( e) go-ahead posterior method <> (f) the opportunity to use method <> 8, China Pharmaceutical Marketing Innovation Strategy <> (a) the characteristics of Chinese consumers, pharmaceutical <> (B ) Chinese pharmaceutical companies marketing innovative strategies <> <> Chapter XXII in 2007 the overall pattern of China’s pharmaceutical industry competition analysis <> First, the overall pattern of regional competition, and <> Second, consumption pattern analysis <> Third, the pattern of evolution of China’s pharmaceutical industry trend <> Third, the analysis of pharmaceutical mergers and acquisitions <> (a) the acquisition of medical knowledge the season <> (b) the pharmaceutical industry brewing a new round of mergers and acquisitions wave <> (c) pharmaceutical companies new round of mergers and acquisitions: from ; <> Twenty-three chapters of the leading Chinese pharmaceutical business case analysis <> a, Harbin Pharmaceutical Group <> (a) Enterprise basic profiles <> (b) production and its main products of < ;> (c) 2007, operation analysis of Harbin Pharmaceutical Group <> (D) analysis of market strategy and competitive advantage <> (e) Future development goals <> Second, the North China Pharmaceutical Group <> (a) Enterprise basic profiles <> (B) industry and its production capacity <> (c) 2007, operation analysis <> (d) competitive strategy and competitive advantage <> ; Third, the Shijiazhuang Pharmaceutical <> (a) Enterprise basic profiles <> (b) 2007 business case analysis <> (c) competition strategy and competitive advantage analysis <> four , Tiantan Biological Products business analysis <> (a) Enterprise basic profiles <> (b) 2007 business case analysis <> (c) the industry competitive strategy and competitive advantage analysis <> Fifth, Johnson & Johnson Pharmaceutical <> (a) Enterprise basic profiles <> (b) 2007 business case analysis <> (c) competition strategy and competitive advantage analysis <> six, Yangtze River Pharmaceutical <> (a) Enterprise basic profiles <> (b) 2007 business case analysis <> (c) the industry competitive strategy and competitive advantage analysis <> seven, Tianjin Zhongxin Pharmaceutical <> (a) Enterprise basic profiles <> (b) 2007 business case analysis <> (c) the industry competitive strategy and competitive advantage analysis <> 8, Shandong Xinhua Pharmaceutical <> (a) Business Basic Overview <> (b) 2007 business case analysis <> (c) the industry competitive strategy and competitive advantage analysis <> September, Tasly <> (a) Enterprise basic profiles < ;> (b) production capacity, technical conditions <> (C) Analysis of business operations in 2007 <> (D) Competitive Strategy and Competitive Advantage <> ten, twenty-fourth slightly China’s pharmaceutical industry, 2008-2010 Chapter trends and prospects <> a, the future trend of China’s pharmaceutical industry in general <> (a) I the pharmaceutical industry outlook <> (b) trends in the field of Chinese medicine retail < ;> two pharmaceutical market, 2008-2010 trend forecast <> (a) the future of the world pharmaceutical market trends <> (b) new trends in the international drug market structure <> (C) in 10 drug development the most important areas of <> (iv) World antibiotic drug market forecast <> (e) chronic pain the world’s major anti-drugs market forecast <> (f) The World Anti-ulcer drug market forecast <> ( g) anti-hypertensive drug market forecast <> (h) the world’s biological technology development forecast <> <> XXV 2008-2010 Chinese medicine characteristics and investment financial investment in environmental studies <> ; First, the pharmaceutical industry investment characteristics of <> (a) the pharmaceutical industry sector-specific <> (b) the status of the pharmaceutical industry <> (c) industry concentration analysis <> (D) upstream and downstream Medicine chain <> (e) the pharmaceutical industry barriers <> Second, the pharmaceutical industry investment and financing environmental studies <> (a) Industrial Policy <> (b) market access conditions <> (C ) industry and market management system <> (d) the relevant policy environment <> Third, the pharmaceutical industry investment status analysis <> (a) of sub-sectors investment value <> (b) pharmaceutical investment industry Five characteristics <> <> Chapter XXVI 2008-2010 pharmaceutical industry and investment income potential wind Yan analysis <> First, the overall potential development of the industry analysis <> (a) investment potential < ;> (b) investment wind Yan <> Second, the key sub-sector analysis of investment income and the wind Yan <> (a) of the curb pharmaceutical industry <> (b) traditional Chinese medicine industry <> ( c) the biopharmaceutical industry <> (4) Medical equipment industry <> <> Chapter XXVII pharmaceutical enterprises in China in 2008-2010 competitive strategy reference <> First, pharmaceutical companies the level of competition analysis <> (a) national policy <> (b) the general trend of merger and reorganization <> (c) merger and reorganization mode <> (d) acquisitions and mergers in question <> II. pharmaceutical companies international business strategy <> (a) International operations present the main problems <> (b) to develop international business strategies of <> (c) to build the core competitiveness of enterprises <> Third, prescription drug manufacturers face the OTC market <> (a) well-modified products <> (b) efforts to expand marketing <> (c) the implementation of integrated marketing <> (D) re-established team <> <> Article VIII 2008-2010 Analysis of China’s pharmaceutical business <> First, the brand pharmaceutical industry analysis <> Second, the Chinese pharmaceutical companies gap analysis <> ; …